CD4 and colorectal carcinoma: The low-PHRDEGscore group exhibited higher immune infiltration (e.g., activated CD8+ and CD4+ T cells), and an exploratory association with immunotherapy response was observed in a non-CRC immunotherapy-treated cohort (IMvigor210).